Efficacy and safety of intensified induction, autologous stem cell transplantation, consolidation and maintenance therapy in patients with newly diagnosed multiple myeloma: a phase2 study

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 30 Sep 2016

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Lenalidomide (Primary) ; Bortezomib; Cyclophosphamide; Dexamethasone; Melphalan
Indications Multiple myeloma
Focus Therapeutic Use
Acronyms JSCT-MM14

26 Sep 2016 Status changed from recruiting to active, no longer recruiting.
03 Aug 2015 Planned initiation date changed from 1 Jul 2015 to 28 Jul 2015 as reported by University Hospital Medical Information Network - Japan.
15 Jul 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com